drugset
Drugs / TU2670
last change May 2025 re-read 3 minutes ago

TU2670

Developed for
endometriosis

Trials 0

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Comparator or background therapy1 trial
Phase 2 NCT05138562 Comparator Aug 2021 → Jan 2024 endometriosis TiumBio Co., Ltd. Completed No outcome recorded

Press releases naming this drug 11 releases

DateIssuerRelease
2025-05-21 TiumBio Co., Ltd. 티움바이오, ‘메리골릭스(TU2670)’ 중국 특허 추가 취득으로 특허기간 연장 tiumbio.com ↗
2025-05-07 TiumBio Co., Ltd. 티움바이오-대원제약, ‘메리골릭스(Merigolix, TU2670/DW-4902)’ 자궁근종 국내 임상 2상 성공 tiumbio.com ↗
2025-03-20 TiumBio Co., Ltd. 티움바이오 파트너 한소제약, 메리골릭스(TU2670)의 보조생식술(ART) 개발 개시로 적응증 확대 tiumbio.com ↗
2024-12-05 TiumBio Co., Ltd. 티움바이오, 자궁내막증 및 자궁근종 치료제 ‘메리골릭스(TU2670)’ 미국 특허 추가 tiumbio.com ↗
2024-05-07 TiumBio Co., Ltd. 티움바이오, ‘메리골릭스(Merigolix, TU2670)’ 자궁내막증 유럽 임상 2a상 성공 tiumbio.com ↗
2023-07-14 Jiangsu Hansoh Pharmaceutical Co., Ltd. HANSOH PHARMA AND TIUMBIO ANNOUNCE CLINICAL TRIAL APPROVAL OF HS-10518/TU2670’ FROM NMPA IN CHINA hspharm.com ↗
2023-07-05 TiumBio Co., Ltd. 티움바이오 파트너사 한소제약, 자궁내막증 치료 신약 'TU2670' 중국 임상1상 IND 승인 tiumbio.com ↗
2023-06-14 TiumBio Co., Ltd. 티움바이오, 자궁내막증 치료제 ‘TU2670’ 유럽 내 특허 추가 취득 tiumbio.com ↗
2023-05-15 TiumBio Co., Ltd. 티움바이오, 자궁내막증 후보물질 ‘TU2670’ 중소벤처기업부 혁신분야 창업패키지 선정 tiumbio.com ↗
2022-09-28 TiumBio Co., Ltd. 티움바이오, 中 한소제약으로부터 자궁내막증 신약후보물질 ‘TU2670’ 기술수출 계약금 수령 tiumbio.com ↗
2022-08-09 Jiangsu Hansoh Pharmaceutical Co., Ltd. HANSOH PHARMA ANNOUNCED STRATEGIC PARTNERSHIP WITH TIUMBIO FOR EXCLUSIVE RIGHTS TO TU2670 IN CHINA hspharm.com ↗

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as TU2670 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05138562 ↗
Route Oral “Orally Administered TU2670” NCT05138562 ↗